Clinical Trial to Assess the Efficacy and Safety of a Novel Cellulite Cream
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01562470|
Recruitment Status : Completed
First Posted : March 23, 2012
Last Update Posted : March 26, 2012
Study Hypothesis: That the test product will reduce thigh cellulite more that the placebo.
This will be a double-blind, placebo-controlled study involving subjects with distinctive cellulite appearance on both thighs. Subjects will apply test cream to one thigh and placebo to the other, by random allocation, and cellulite appearance will be measured at week 0, 8 and 16. Cellulite photographs will also be assessed by a (study blinded) trial researcher, who will assess cellulite appearance on a precisely-measured upper leg area. The subjects' own perception of cellulite appearance, from their diaries, will be numerically coded, and all three measures will be collated and analysed statistically.
|Condition or disease||Intervention/treatment||Phase|
|Thigh Cellulite||Other: Cellulite reduction cream||Phase 1|
Twenty subjects will be recruited through advertisements in local newspapers. Eligible subjects will be asked to visit the lab, where they will sign an information/consent form and answer a series of questions to determine their eligibility. If eligible, each subject will be asked to have their upper leg cellulite photographed, and thigh circumference will be measured. They will be given two containers of cream, labelled R (for right thigh) and L (for left thigh) which have been pre-weighed in their containers, and they will be instructed on how to apply the cream. They will record their perception of the amount of cellulite on a weekly basis, and they will also record any adverse events. At the two and four-month time-points, they will return to the lab with their diaries and cream. The cream in its container will be weighed to ensure compliance, and the diaries will be examined and returned to the participants. Thighs will again be photographed and circumference measured. At the four-month visit, subjects will return any remaining product for weighing, as well as their diaries for analysis.
Photographs from each subject will be coded and cellulite marks assessed by arranging the photographs chronologically, i.e. timepoint 1, timepoint 2 and timepoint 3. They will also be assessed by a (blinded) trial researcher, who will assess cellulite appearance on a precisely-measured upper leg area in the photographs. The subjects' own perception of cellulite appearance, from their diaries, will be numerically coded, and all three measures will be collated and analysed statistically.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Clinical Trial to Assess the Efficacy and Safety of a Novel Cellulite Cream in Reducing the Appearance of Cellulite in Human Subjects|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||December 2011|
Experimental: herbal-based cellulite cream
Trial subjects will apply the treatment cream to one thigh and placebo to the other thigh, by random allocation.
Other: Cellulite reduction cream
1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
- thigh cellulite appearance [ Time Frame: 16 weeks ]Reduction of cellulite appearance, as assessed by photographs, self-assessment and clinician assessment.
- Uper leg circumference and fat content [ Time Frame: 16 weeks ]Reduction of upper leg circumference as measured by cm tape measure, and reduction of fat content of upper leg as measured using fat calipers
- Presence/absence of adverse reactions [ Time Frame: 16 weeks ]Any incidence of an adverse event or events will be recorded in an Adverse Events Diary, and results collated and reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01562470
|Nutrasource Diagnostics Inc.|
|Guelph, Ontario, Canada, N1H1Y3|
|Study Director:||Steven Traplin, MD||Nutrasource Diagnostics Inc.|
|Principal Investigator:||Maggie Laidlaw, Ph.D.||Nutrasource Diagnostics Inc.|